First‐in‐human study of the cancer peptide vaccine TAS0313 in patients with advanced solid tumors

TAS0313, a novel cancer vaccine cocktail, was developed to overcome the disadvantages of previously developed short and long peptide vaccines; it comprises several long peptides targeting multiple cancer antigens. We evaluated TAS0313 monotherapy in Japanese patients with advanced solid tumors for w...

Descripción completa

Detalles Bibliográficos
Autores principales: Kondo, Shunsuke, Shimizu, Toshio, Koyama, Takafumi, Sato, Jun, Iwasa, Satoru, Yonemori, Kan, Fujiwara, Yutaka, Shimomura, Akihiko, Kitano, Shigehisa, Tamura, Kenji, Yamamoto, Noboru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019195/
https://www.ncbi.nlm.nih.gov/pubmed/33615628
http://dx.doi.org/10.1111/cas.14765

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019195/
https://www.ncbi.nlm.nih.gov/pubmed/33615628
http://dx.doi.org/10.1111/cas.14765

Ejemplares similares